NIH R21 Winners: 1,521 New Awards in FY2025

Current route, checked October 20, 2026: The October 16 new-application date has passed. PA-25-304 and PA-25-306 list February 16, 2027 as the next new-application date and November 16, 2026 as the next resubmission or revision date. Confirm organizational eligibility and institute participation through the exact notice. Use the NIH R21 guide, NIH grants guide, R01/R21/R03/K comparison, parent R21 no-trial record, parent R21 trial-required record, and the free Grantsights grant search before assigning staff time.

According to NIH's R21 activity-code page (opens in a new tab), R21 supports exploratory or developmental research and generally allows up to 2 years, up to $275,000 in combined direct costs, and no more than $200,000 in one year. NIH also states that the mechanism cannot be renewed, preliminary data are not required unless the notice says otherwise, and the Research Strategy generally has a 6-page limit.

According to NIH RePORTER, the public search (opens in a new tab) provides the project numbers, recipients, investigators, fiscal years, award amounts, and administering institutes used here. The phrase "NIH R21 winners" still needs a source-unit rule: Type 1 means new, Type 5 means a later noncompeting budget period, and Type 2 would mean renewal. The complete FY2025 R21 pull had no Type 2 rows.

What Counts as an NIH R21 Winner?

NIH's current application-type definitions (opens in a new tab) explain the project-number prefixes:

This distinction changes the answer materially. Calling all 3,086 project-year records winners would double the FY2025 new-award count. The accurate search answer is 1,521 Type 1 awards.

The October 9 pull added 13 FY2025 rows (mostly recipient-change records) after the July 29 snapshot, and FY2024 gained 1 record. RePORTER can backfill or revise fiscal-year records, so every portfolio claim needs a retrieval date and a reproducible count check.

10 High-Award New FY2025 R21 Records

The following preview contains only Type 1 new awards:

Across all 1,521 Type 1 records, the median total award amount was $401,566 and the average was $340,903. The median can exceed the average because many lower first-year records pull the mean down while a large middle group reflects total costs around a two-year R21 structure.

For example, Vanderbilt University Medical Center received the largest Type 1 row in this pull at $700,000. That is a real new-award record, but it is not a normal direct-cost target. RePORTER reports total award amounts, while the parent notices control direct costs. Facilities and administrative costs, award timing, and notice-specific terms can make a public total-cost row exceed the familiar $275,000 direct-cost limit.

The warning is simple: do not copy a winner's RePORTER amount into a budget. Start with the selected notice, separate direct from total costs, and confirm institute policy.

FY2024 to FY2025 R21 Movement

Do not turn the decline from 1,885 to 1,521 Type 1 records into an R21 success rate. RePORTER gives funded project records, not the complete application denominator required for a success-rate calculation.

According to NIH's success-rate data source (opens in a new tab), success-rate analysis belongs to the published application and award tables. According to NIH's application-type page, a Type 1 row identifies an initial request for support of a project that had not been funded. Those two sources answer different questions.

Top R21 States and NIH Institutes

The state table describes portfolio capacity, not applicant odds. California's 373 project-year rows do not mean a California PI has an easier review. Compare the topic, organization setting, institute, project maturity, and study area instead.

Institute participation also changes by notice. PA-25-304, the no-trial parent route, added NCATS participation on July 16, 2026. The clinical-trial-required parent route has a different institute list. A high NIAID record count does not establish that another institute accepts the proposed route.

Top FY2025 R21 Recipient Organizations

R21 is not reserved for early-career or low-resource applicants. Research-intensive universities and hospitals lead the public count. A smaller institution can still compete, but its application needs clear evidence of methods, access, facilities, collaborators, and a bounded two-year output.

R21 Fit Decision Checklist

The strongest R21 route is a focused exploratory question, not an R01 compressed into six pages.

One applicant with a new imaging method and ready pilot samples may have an R21-shaped feasibility question. One team with three mature aims, multi-site recruitment, and a long staff runway likely has R01-shaped work. This example is a route screen, not an award prediction.

Based on our analysis, the common mistake is choosing R21 only because preliminary data are thin. That reasoning is weak. A better sentence is: "This R21 resolves one consequential uncertainty within two years, and the result determines whether a larger project should proceed."

Current Parent R21 Routes

Route dates checked October 20, 2026: both parent notices expire January 8, 2028. The October 16 new-application date has passed; the next listed dates are:

According to PA-25-304, allowed application types are new, resubmission, and revision. According to PA-25-306, the same three types are allowed and at least one clinical trial must be proposed. Neither parent notice allows a renewal application.

The exact notice controls. Institute-specific R21 notices may use other dates, topics, budgets, or participation rules.

What RePORTER Doesn't Tell You

The hard truth is that winner history can make an ill-fitting R21 look safer than it is. RePORTER cannot tell whether the study is exploratory enough, whether the trial classification is correct, whether reviewers will accept the central risk, or whether a participating institute wants the topic.

Avoid treating a similar title as permission to apply. The strongest comparison matches the topic, institute, project stage, organization setting, trial posture, and current notice. If the winner pattern is mostly R01 work or the selected institute does not participate, stop and compare another route.

Apply, Wait, or Shift Routes

The largest red flag is "R21 is easier." R21 is smaller and structurally different, not a low-friction R01. The application still needs a credible path to an interpretable result.

What This Page Covers

This public page provides the current new-winner count, selected Type 1 records, award amounts, states, institutes, recipients, current parent routes, and fit guidance. For deeper slicing by topic or repeat recipients, NIH RePORTER (opens in a new tab) itself is free and filterable. To compare R21 with other programs your organization may fit, use the free Grantsights grant search or the eligibility checker.

What changed

• October 20, 2026: corrected the next parent R21 new-application date from October 16, 2026, which has passed, to February 16, 2027. Rechecked PA-25-304 and PA-25-306; the next resubmission or revision date remains November 16, 2026. The award-data pull and counts remain dated October 9, 2026.

Sources

• NIH R21 activity code: grants.nih.gov (opens in a new tab)
• NIH application types: grants.nih.gov (opens in a new tab)
• NIH RePORTER search: reporter.nih.gov (opens in a new tab)
• NIH RePORTER API: api.reporter.nih.gov (opens in a new tab)
• NIH success-rate data: report.nih.gov (opens in a new tab)
• PA-25-304 parent R21, clinical trial not allowed: grants.nih.gov (opens in a new tab)
• PA-25-306 parent R21, clinical trial required: grants.nih.gov (opens in a new tab)

Related Guides

• NIH R21 grant guide
• NIH grants complete guide
• NIH R01 grant guide
• NIH R01 award history
• NIH R01 success-rate data
• NIH K01 award history
• NIH R01, R21, R03, and K awards comparison
• Free grant databases
• NIH R15 AREA and REAP award history
• NIH New Innovator (DP2) winners